Glob Reg Health Technol Assess 2025 | DOI: 10.33393/grhta.2025.3199 | Abad et al

MCDA EVIDENCE MATRIX

Legal Disclaimer

The information contained in this document is CONFIDENTIAL.

INTRODUCTION

DESCRIPTION

INTERVENTION: DISEASE: SCOPE: COMPARATOR:	
INTERVENTION DESCRIPTION	
COMPARATOR	

TREATMENT-RELATED CRITERIA					
CRITERIA	RELEVANT SUMMARISED DATA	SCORE			
EFFICACY/EFFECTIVENESS		□ 5 Much safer/more tolerable than comparator			
Sub-criteria:		□ 4			
Magnitude of clinical benefit or health outcomes					
compared to the comparator		□ 2			
Duration of health benefit		□ 1			
		□ 0 No difference			
		□ -1			
		□ -2			
		□ -3			
		□ -4			
		□ -5 Much less safe/tolerable than the comparator			
REFLECTIONS BEHIND YOUR SCO	REFLECTIONS BEHIND YOUR SCORE (MANDATORY FIELD):				

TREATMENT-RELATED CRITERIA		
CRITERIA	RELEVANT SUMMARISED DATA	SCORE
SAFETY/TOLERABILITY		□ 5 Much safer/more tolerable than comparator
Sub-criteria:		
 Percentage of adverse events 		
 Type (severity) of grade 3 and 4 adverse events 		
 Frequency grade 3 and 4 adverse events 		□ 1 □ 0 No difference
Percentage of patients who		□ -1
stop treatment due to adverse events		□ -2
		□ -3
		□ -4
		□ -5 Much less safe/tolerable than the comparator
REFLECTIONS BEHIND YOUR SCOP	RE (MANDATORY FIELD):	

TREATMENT-RELATED CRITERIA			
CRITERIA	RELEVANT SUMMARISED DATA	SCORE	
PATIENT REPORTED OUTCOMES (PROs)		□ 5 The intervention highly improve PROs	
Sub-criteria:		□ 4	
Improvement in the health-related		□ 3	
quality of life of patients		□ 2	
 Patient preference and satisfaction with available 		□ 1	
therapeutic alternatives		□ 0 No difference	
		□ -1	
		□ -2	
		□ -3	
		□ -4	
		□ -5 The intervention worsen PROs	
REFLECTIONS BEHIND YOUR SCORE (MANDATORY FIELD):			

	CRITERIA	RELEVANT SUMMARISED DATA	SCORE
TYPE BENEF	OF THERAPEUTIC		□ 5 Curative treatment/life- saving benefit
Sub-cr	teria:		□ 4
•	Symptom reduction		
•	Modification of clinical course (interruption or slowing of progression)		□ 2 □ 1
•	Cure or impairment of mortality		□ 0 No therapeutic benefit

SCORE				
□ 4				
□ 2				
□ 1				
□ 0 No difference in expenditure				
□ -1				
□ -2				
□ -3				
□ -4				
□ -5 Substantial additional expenses				
REFLECTIONS BEHIND YOUR SCORE (MANDATORY FIELD):				
-				

TREATMENT-RELATED CRITERIA		
CRITERIA	RELEVANT SUMMARISED DATA	SCORE
NON-MEDICAL (INDIRECT) COSTS		□ 5 Substantial savings
Sub-criteria:		□ 4
 Impact on patients and caregivers' productivity 		
 Financial impact on patients and caregivers 		□ 2 □ 1
Costs to the social care system		O No difference in expenditure
		□ -1
		□ -2
		□ -3
		□ -4
		□ -5 Substantial additional expenses
REFLECTIONS BEHIND YOUR SCORE (N	IANDATORY FIELD):	

TREATMENT-RELATED CRITERIA		
CRITERIA	RELEVANT SUMMARISED DATA	SCORE
QUALITY OF EVIDENCE AND GRADE OF RECOMMENDATION		□ 5 Highly relevant and complete evidence for the
Sub-criteria:		intervention.
• Validity		
Relevance		□ 3
Completeness of evidence		□ 2
• Type of evidence		□ 1
		□ 0 Very low-quality evidence for the intervention
		Note: Scores ≥ 3 are considered significant in the MCDA methodology.
REFLECTIONS BEHIND YOUR SCORE	(MANDATORY FIELD):	

BIBLIOGRAPHY